NeoSoma
Groton, US · Founded 2019 · Delaware corporation · 12 employees on LinkedIn · 3 known investors
Find your way into NeoSoma
954 people in our graph share verified history with the NeoSoma team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows Aly Abayazeed · together at Stanford University (overlapped)
×4knows the team · via Stanford University
×3knows the team · via Stanford University School of Medicine
×3knows the team · via Viz.ai
knows the team · via Sharp HealthCare
Neosoma offers a cloud software platform that uses AI to map, measure, contour, and track brain tumor lesions from MRI scans over time. The FDA-cleared tool is built for multidisciplinary neuro-oncology teams—including neurosurgeons and radiation oncologists—to support tumor assessment, treatment planning, and tumor board decisions.
Founders & leadership
NeoSoma was founded in 2019 by Aly Abayazeed.
AA
Aly AbayazeedinCo-founder & Chief Medical Officer2019–2024Aly Abayazeed holds a degree in informatics and health care management from Stanford and previously served as co-founder and Chief Medical Officer at a radiology AI company, where he worked on FDA regulatory clearance and clinical deployment of medical AI tools. He is now Executive Officer and Director at NeoSoma.
JL
John LiedtkyinIndependent ConsultantHe brings experience in medical technology commercialization, including product development and launch of medical device and software products, with prior roles across startups and larger medtech organizations focused on neurologic and neuro-oncology applications.
KK
Kenneth KolodziejExecutive
MH
Michael HillExecutive
Board
KR
OI
Oleg IkhelsonBoard director
DM
Deborah MillinBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$10.2M disclosed across 5 rounds · 2020–2026
▶$3.5MraisedMar 2026 · 52 investors · Other TechnologyRule 506(b)
▶$3.5MraisedMar 2026 · 52 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Michael HillExecutive Officer
- Kenneth KolodziejExecutive Officer, Director
- Will IselinDirector
- Kevin RichardDirector
- Offering amount
- $5.8M
- Amount sold
- $3.5M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$345KraisedJan 2025 · 5 investors · Other TechnologyRule 506(b)
▶$345KraisedJan 2025 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin RichardDirector
- Deborah MillinDirector
- Kenneth KolodziejExecutive Officer, Director
- John LiedtkyExecutive Officer
- Michael HillExecutive Officer
- Oleg IkhelsonDirector
- Offering amount
- $800K
- Amount sold
- $345K
- Proceeds to insiders
- $150K
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedJul 2024 · 54 investors · Other TechnologyRule 506(b)
▶$5.1MraisedJul 2024 · 54 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- John LiedtkyExecutive Officer
- Kenneth KolodziejExecutive Officer, Director
- Kevin RichardDirector
- Oleg IkhelsonDirector
- Michael HillExecutive Officer
- Deborah MillinDirector
- Offering amount
- $5.8M
- Amount sold
- $5.1M
- Proceeds to insiders
- $100K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedFeb 2024 · 15 investors · Other TechnologyRule 506(b)
▶$1.2MraisedFeb 2024 · 15 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth KolodziejExecutive Officer, Director
- Kevin RichardDirector
- Deborah MillinDirector
- Aly AbayazeedExecutive Officer, Director
- Offering amount
- $3.1M
- Amount sold
- $1.2M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$75KraisedNov 2020 · 2 investors · Other TechnologyRule 506(b)
▶$75KraisedNov 2020 · 2 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth KolodziejExecutive Officer, Director
- Aly AbayazeedExecutive Officer, Director
- Offering amount
- $750K
- Amount sold
- $75K
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapIcometrix4 shared keywordsIcometrix develops AI-powered medical imaging software for analyzing brain MRI scans to help clinicians diagnose and monitor neurological conditions like Alzheimer's disease, stroke, and traumatic brain injury. The company serves healthcare providers and patients seeking advanced diagnostic clarity for brain disorders.
Agenus3 shared keywordsAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
Companies competing with NeoSoma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does NeoSoma do?
- Neosoma offers a cloud software platform that uses AI to map, measure, contour, and track brain tumor lesions from MRI scans over time. The FDA-cleared tool is built for multidisciplinary neuro-oncology teams—including neurosurgeons and radiation oncologists—to support tumor assessment, treatment planning, and tumor board decisions.
- Who founded NeoSoma?
- NeoSoma was founded by Aly Abayazeed in 2019.
- Who are NeoSoma's investors?
- NeoSoma's investors include Beacon Angels, Launchpad Venture Group, Alliance of Angels.
- How much funding has NeoSoma raised?
- NeoSoma has disclosed $10.2M raised across 5 rounds.
- Where is NeoSoma headquartered?
- NeoSoma is headquartered in Groton, US.